Neuroprotection in glaucoma: Recent and future directions

Current Opinion in Ophthalmology

Volumn 22, Issue 2, 2011, Pages 78-86

  Danesh Meyer, Helen V ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

glaucoma; neuroprotection; optic nerve disease; retinal ganglion cells

Indexed keywords

BIS(7) TACRINE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRIMONIDINE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CILNIDIPINE; CILOSTAZOL; ERYTHROPOIETIN; GLUTAMATE RECEPTOR ANTAGONIST; GRANULOCYTE COLONY STIMULATING FACTOR; LOMERIZINE; MEMANTINE; MONOCYTE CHEMOTACTIC PROTEIN 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NEUROPEPTIDE; NEUROPEPTIDE NAP; NEUROPROTECTIVE AGENT; NIPRADILOL; PYROGLUTAMIC ACID; TACRINE DERIVATIVE; TAFLUPROST; UNCLASSIFIED DRUG; VALPROIC ACID;

AXONAL INJURY; DISEASE MODEL; DRUG MECHANISM; EMBRYONIC STEM CELL; GLAUCOMA; INTRAOCULAR PRESSURE; MUELLER CELL; NERVE FIBER TRANSECTION; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; OPTIC NERVE INJURY; PRIORITY JOURNAL; RETINA GANGLION CELL; REVIEW; STEM CELL TRANSPLANTATION;

ANIMALS; BIOMEDICAL RESEARCH; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MICE; NEUROPROTECTIVE AGENTS; OPTIC NERVE DISEASES; RETINAL GANGLION CELLS;

EID: 79951956270     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32834372ec     Document Type: Review

References (71)

1. Danias J, Shen F, Kavalarakis M, et al. Characterization of retinal damage in the episcleral vein cauterization rat glaucoma model. Exp Eye Res 2006; 82:219-228. (Pubitemid 43124107)
2. Levkovitch-Verbin H, Quigley HA, Martin KR, et al. Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma in rats. Invest Ophthalmol Vis Sci 2002; 43:402-410. This paper outlines one of the most commonly employed techniques of inducing glaucomatous damage in a rodent model.
3. Johnson EC, Guo Y, Cepurna WO, Morrison JC. Neurotrophin roles in retinal ganglion cell survival: lessons from rat glaucoma models. Exp Eye Res 2009; 88:808-815. This review details the pathophysiology of neurotrophin deprivation and comprehensively examines the response of neurotrophin signalling in rat glaucoma models.
4. Sappington RM, Carlson BJ, Crish SD, Calkins DJ. The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice. Invest Ophthalmol Vis Sci 2010; 51:207-216.
5. Cone FE, Gelman SE, Son JL, et al. Differential susceptibility to experimental glaucoma among 3 mouse strains using bead and viscoelastic injection. Exp Eye Res 2010; 91:415-424. This study demonstrates that different strains of mice have differential susceptibility to experimental glaucoma.
6. Anderson MG, Smith RS, Hawes NL, et al. Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. Nat Genet 2002; 30:81-85.
7. John SW, Smith RS, Savinova OV, et al. Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. Invest Ophthalmol Vis Sci 1998; 39:951-962. (Pubitemid 28196680)
8. Levkovitch-Verbin H, Quigley HA, Kerrigan-Baumrind LA, et al. Optic nerve transection in monkeys may result in secondary degeneration of retinal ganglion cells. Invest Ophthalmol Vis Sci 2001; 42:975-982. (Pubitemid 32289792)
9. Sakamoto K, Kawakami T, Shimada M, et al. Histological protection by cilnidipine, a dual L/N-type Ca(2+) channel blocker, against neurotoxicity induced by ischemia-reperfusion in rat retina. Exp Eye Res 2009; 88:974-982.
10. Fitzgerald M, Payne SC, Bartlett CA, et al. Secondary retinal ganglion cell death and the neuroprotective effects of the calcium channel blocker lomerizine. Invest Ophthalmol Vis Sci 2009; 50:5456-5462.
11. Fang JH, Wang XH, Xu ZR, Jiang FG. Neuroprotective effects of bis(7)-tacrine against glutamate-induced retinal ganglion cells damage. BMC Neurosci 2010; 11:31-40.
12. Oono S, Kurimoto T, Nakazawa T, et al. Pyroglutamic acid promotes survival of retinal ganglion cells after optic nerve injury. Curr Eye Res 2009; 34:598-605.
13. Dong CJ, Guo Y, Agey P, et al. Alpha-2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci 2008; 49:4515-4522.
14. Ma K, Xu L, Zhang H, et al. Effect of brimonidine on retinal ganglion cell survival in an optic nerve crush model. Am J Ophthalmol 2009; 147:326-331.
15. Goldenberg-Cohen N, Dadon-Bar-El S, Hasanreisoglu M. Possible neuroprotective effect of brimonidine in a mouse model of ischaemic optic neuropathy. Clin Exp Ophthalmol 2009; 37:718-729.
16. Hernandez M, Urcola JH, Vecino E. Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments. Exp Eye Res 2008; 86:798-806.
17. Parrilla-Reverter G, Agudo M, Sobrado-Calvo P, et al. Effects of different neurotrophic factors on the survival of retinal ganglion cells after a complete intraorbital nerve crush injury: a quantitative in vivo study. Exp Eye Res 2009; 89:32-41.
18. Lebrun-Julien F, Morquette B, Douillette A, et al. Inhibition of p75NTR in glia potentiates TrkA-mediated survival of injured retinal ganglion cells. Mol Cell Neurosci 2009; 40:410-420.
19. Bai Y, Xu J, Brahimi F. An agonistic TrkB mAb causes sustained TrkB activation, delays RGC death, and protects the retinal structure in optic nerve axotomy and in glaucoma. Invest Ophthalmol Vis Sci 2010; 51:4722-4731.
20. Pease ME, Zack DJ, Berlinicke C, et al. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci 2009; 50:2194-2200.
21. Fu QL, Hu B, Wu W, et al. Blocking LINGO-1 function promotes retinal ganglion cell survival following ocular hypertension and optic nerve transection. Invest Ophthalmol Vis Sci 2008; 49:975-985.
22. Grozdanic SD, Lazic T, Kuehn MH. Exogenous modulation of intrinsic optic nerve neuroprotective activity. Graefes Arch Clin Exp Ophthalmol 2010; 248:1105-1116.
23. Weber AJ, Viswanathan S, Ramanathan C, Harman CD. Combined application of BDNF to the eye and brain enhances ganglion cell survival and function in the cat after optic nerve injury. Invest Ophthalmol Vis Sci 2010; 51:327-334.
24. Koriyama Y, Tanii H, Ohno M, et al. A novel neuroprotective role of a small peptide from flesh fly, 5-S-GAD in the rat retina in vivo. Brain Res 2008; 1240:1960-2203.
25. Rojas JC, John JM, Lee J, Gonzalez-Lima F. Methylene blue provides behavioural and metabolic neuroprotection against optic neuropathy. Neurotox Res 2009; 15:260-273.
26. Peng PH, Chiou LF, Chao HM, et al. Effects of epigallocatechin-3-gallate on rat retinal ganglion cells after optic nerve axotomy. Exp Eye Res 2010; 90:e528-e534.
27. Xie J, Jiang L, Zhang T, et al. Neuroprotective effects of epigallocatchin-3-gallate (EGCG) in optic nerve crush model in rats. Neurosci Lett 2010; 479:26-30.
28. Bull ND, Irvine KA, Franklin RJM, Martin KR. Transplanted oligodendrocyte precursor cells reduce neurodegeneration in a model of glaucoma. Invest Ophthalmol Vis Sci 2009; 50:4244-4253.
29. Johnson TV, Bull ND, Hunt DP, et al. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Invest Ophthalmol Vis Sci 2010; 51:2051-2059.
30. Zwart I, Hill AJ, Al-Allaf F, Shah S, et al. Umbilical cord blood mesenchymal stromal cells are neuroprotective and promote regeneration in a rat optic tract model. Exp Neurol 2009; 216:439-448.
31. Na L, Xiao-rong L, Jia-qin Y. Effects of bone-marrow mesenchymal stem cells transplanted into vitreous cavity of rat injured by ischemia/reperfusion. Graefes Arch Clin Exp Ophthalmol 2009; 247:503-514.
32. Hill AJ, Zwart I, Samaranayake AN, et al. Rat neurosphere cells protect axotomized rat retinal ganglion cells and facilitate their regeneration. J Neurotrauma 2009; 26:1147-1156.
33. Aoki H, Hare A, Niwa M, et al. Transplantation of cells from eye-like structures differentiated from embryonic stem cells in vitro and in vivo regeneration of retinal ganglion-like cells. Graefes Arch Clin Exp Ophthalmol 2007; 246:255-265.
34. Bull ND, Limb A, Martin KR. Human Müller stem cell (MIO-M1) transplantation in a rat model of glaucoma: survival, differentiation, and integration. Invest Ophthalmol Vis Sci 2008; 49:3449-3456.
35. Tsai RK, Chang CH, Wang HZ, et al. Neuroprotective effects of recombinant human granulocyte colony-stimulating factor (G-CSF) in neurodegeneration after optic nerve crush in rats. Exp Eye Res 2008; 87:242-250.
36. Chiu K, Yeung S, So K, Chang RCC. Modulation of morphological changes of microglia and neuroprotection by monocyte chemoattractant protein-1 in experimental glaucoma. Cell Mol Immun 2010; 7:61-68.
37. Bosco A, Inman DM, Steele MR, et al. Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. Invest Ophthalmol Vis Sci 2008; 49:1437-1446.
38. Biermann J, Grieshaber P, Goebel U, et al. Regeneration in injured retinal ganglion cells. Invest Ophthalmol Vis Sci 2010; 51:526-534.
39. Kanamori A, Naka M, Fukuda M, Nakamura M. Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Graefes Arch Clin Exp Ophthalmol 2009; 247:1353-1360.
40. Jehle T, Dimitriu C, Auer A, et al. The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush. Graefes Arch Clin Exp Ophthalmol 2008; 246:1255-1263.
41. Karim MZ, Sawada A, Mizuno K, et al. Neuroprotective effect of nipradilol [3,4-dihydro-8-(2-hydroxy-3-isopropylamino)-propoxy-3-nitroxy-2H-1-benzopyran] in a rat model of optic nerve degeneration. J Glaucoma 2009; 18:26-31.
42. Fu Q, Wu EW, Wang H, et al. Up-regulated endogenous erythropoietin/ erythropoietin receptor system and exogenous erythropoietin rescue retinal ganglion cells after chronic ocular hypertension. Cell Mol Neurobiol 2008; 28:317-329. (Pubitemid 351253068)
43. Yang H, Hirooka K, Fukuda K, Shiraga F. Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. Invest Ophthalmol Vis Sci 2009; 50:5800-5804.
44. Kanamori A, Catrinescu M-M, Mahammed A, et al. Neuroprotection against superoxide anion radical by metallocorroles in cellular and murine models of optic neuropathy. J Neurochem 2010; 114:488-498.
45. Kashimoto R, Kurimoto T, Miyoshi T, et al. Cilostazol promotes survival of axotomized retinal ganglion cells in adult rats. Neurosci Lett 2008; 436:116-119.
46. Levin LA. Retinal ganglion cells and neuroprotection for glaucoma. Surv Ophthalmol 2003; 48:S1-S24.
47. Hare WA, WoldeMussie E, Weinreb RN, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: structural measures. Invest Ophthalmol Vis Sci 2004; 45:2640-2651. (Pubitemid 38998860)
48. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmologica 2009; 87:450-454. This is an important review that outlines the basis of the potential for NMDA inhibitors as neuroprotective agents.
49. Lagreze WA, Knorle R, Bach M, Feurstein TJ. Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest Ophthalmol Vis Sci 1998; 39:1063-1066. (Pubitemid 28196695)
50. Allergan Inc. Press releases on Memantine Trials. http://www.allergan. com/newsroom/index.htm.
51. Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent. An evidence-based review. Arch Ophthalmol 2009; 127:402-406. A review of the preclinical and clinical investigations relating to brimonidine and its potential neuroprotective effect.
52. Saragovi HU, Hamel E, Di Polo A. A neurotrophic rationale for the therapy of neurodegenerative disorders. Curr Alzheimer Res 2009; 6:419-423.
53. Cooper NG, Laabich A, Fan W, Wang X. The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells. Prog Brain Res 2008; 173:521-540.
54. Weber AJ, Harman CD, Viswanathan S. Effects of optic nerve injury, glaucoma, and neuroprotection on the survival, structure, and function of ganglion cells in the mammalian retina. J Physiol 2008; 586:4393-4400. This study outlines the underlying basis for the use of BDNF as a neuroprotective agent and provides direction for future treatment strategies using neurotrophins.
55. Quigley HA, McKinnon SJ, Zack DJ, et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci 2000; 41:3460-3466.
56. Lambiase A, Aloe L, Centofanti M, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. Proc Natl Acad Sci U S A 2009; 106:13469-13474.
57. Schober MS, Chidlow G, Wood JP, Casson RJ. Bioenergetic-based neuroprotection and glaucoma. Clin Experimental Ophthalmol 2008; 36:377-385. This review provides a detailed overview on the role of bioenergetics in neuroprotection.
58. Ji D, Li GY, Osborne NN. Nicotinamide attenuates retinal ischemia and light insults to neurons. Neurochem Int 2007; 52:786-798.
59. Nucci C, Tartaglione R, Cerulli A, et al. Retinal damage caused by high intraocular pressure-induced transient ischemia is prevented by coenzyme Q10 in rat. Int Rev Neurobiol 2007; 82:397-406.
60. Russo R, Cavaliere F, Rombolà L, et al. Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection. Prog Brain Res 2008; 173:575-582.
61. Munemasa Y, Ahn JH, Kwong JM, et al. Redox proteins thioredoxin 1 and thioredoxin 2 support retinal ganglion cell survival in experimental glaucoma. Gene Ther 2009; 16:17-25.
62. Tezel G. TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res 2008; 173:409-421. This paper is an outstanding review that focuses on the evidence supporting the involvement of TNF-alpha signalling in glaucomatous injury and the potential role of treatment targets. It also discusses the differential responses of RGCs and glia to TNF-alpha.
63. Nakazawa T, Nakazawa C, Matsubara A, et al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci 2006; 26:12633-12641. (Pubitemid 44904557)
64. Tulsawani R, Kelly LS, Fatma N, et al. Neuroprotective effect of peroxiredoxin 6 against hypoxia-induced retinal ganglion cell damage. BMC Neuroscience 2010; 11:125-139.
65. Wax MB, Tezel G. Immunoregulation of retinal ganglion cell fate in glaucoma. Exp Eye Res 2009; 88:825-830. This review provides an overview on the role of immunoregulation in RGC survival following injury.
66. Frank T, Schlachetzki JCM, Göricke B, et al. Both systemic and local application of granulocyte-colony stimulating factor (G-CSF) is neuroprotective after retinal ganglion cell axotomy. BMC Neurosci 2009; 10:49-59.
67. Yazulla S. Endocannabinoids in the retina: from marijuana to neuroprotection. Prog Ret Eye Res 2008; 27:501-526.
68. Chan HC, Chang RCC, Ip AKC. Neuroprotective effects of Lycium barbarum Lynn on protecting retinal ganglion cells in an ocular hypertension model of glaucoma. Exp Neurol 2007; 203:269-273.
69. Parisi V, Coppola G, Centofanti M, et al. Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog Brain Res 2008; 173:541-554.
70. Danesh-Meyer HV, Levin LA. Neuroprotection: extrapolating from neurologic diseases to the eye. Am J Ophthalmol 2009; 148:186-191. This commentary provides insights into some of the issues involved in the failure of translation in central nervous system neuroprotection studies.
71. Levin LA, Danesh-Meyer HV. Lost in translation: bumps in the road between bench and bedside. JAMA 2010; 303:1533-1534.